---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000065"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:43:33.738621+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Recursion appoints Robert Hershberg as new board chair; Martin Chavez to exit at 2024 annual meeting

## Summary
- Martin Chavez not standing for re-election; term ends at 2024 Annual Meeting; no disagreement with company.
- Board elects Robert Hershberg as new Chair effective at 2024 Annual Meeting; board size reduced from 9 to 8.
- Hershberg, board member since May 2020, is CEO of HilleVax and former Celgene executive with 25+ years experience.
- Auditor changed to PricewaterhouseCoopers for FY 2024 engagement, as previously disclosed on May 9, 2024.

## SEC filing metadata
- accession: 0001601830-24-000065
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 4.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000065/0001601830-24-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000065/rxrx-20240521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000065
- JSON: https://secwatch.observer/filing/0001601830-24-000065.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000065.txt

## Source-grounded claims
- claim_id: 7f1974c52b
  claim: Robert Hershberg changed role as Chair of the Board at RECURSION PHARMACEUTICALS, INC..
  evidence_excerpt: the Board elected Robert Hershberg, M.D., Ph.D. as the Chair of the Board, effective at the 2024 Annual Meeting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000065/0001601830-24-000065-index.htm
- claim_id: 8b43d837e6
  claim: R. Martin Chavez departed as Chair of the Board at RECURSION PHARMACEUTICALS, INC..
  evidence_excerpt: R. Martin Chavez, Ph.D., Chair of the Board and member of the Audit Committee of the Board, informed the Company that he will no longer stand for re-election to the Board as a Class III Director at the 2024 Annual Meeting of Stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000065/0001601830-24-000065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.